KMT2A重排急性淋巴细胞白血病的结局:MD Anderson经验
该研究回顾性分析了1984至2019年在MD Anderson治疗的1102例成人ALL患者,其中50例(5%)存在KMT2A重排,包括42例t(4;11)/KMT2A-AFF1和8例其他伙伴基因。研究确认任何KMT2A重排ALL预后均差,HSCT可能改善结局。
要点
- 成人ALL中KMT2A重排占5%,t(4;11)/KMT2A-AFF1占84%。
- KMT2A重排ALL完全缓解率88%,但5年OS仅18%。
核心结论
- 任何KMT2A重排的成人ALL预后均差,5年OS率仅18%。
- 异基因造血干细胞移植可能改善KMT2A重排ALL患者的生存。
研究设计与样本
- 回顾性单中心研究,纳入1984至2019年MD Anderson治疗的1102例成人ALL患者。
- 共识别50例(5%)KMT2A重排患者,其中42例(84%)为t(4;11)/KMT2A-AFF1,8例(16%)为其他伙伴基因。
- 中位年龄45岁(范围18-78岁),中位白细胞计数109.0×10^9/L(范围0.5-1573.0)。
主要发现
- 完全缓解率88%,流式细胞术检测的微小残留病阴性率在完全缓解时为41%(随访期间总体为76%)。
- 末次随访时14例患者存活,5年总生存率为18%(95%CI 9%-35%)。
临床怎么用
- 对成人ALL患者应进行KMT2A重排检测,以识别高危亚群。
- KMT2A重排ALL患者应考虑异基因造血干细胞移植以改善长期生存。
局限性
- 回顾性单中心研究,样本量较小(50例KMT2A重排患者)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute lymphoblastic leukemia (ALL) with t(4;11)(q21;q23)-KMT2A-AFF1 is associated with a poor prognosis. The impact of KMT2A rearrangements other than t(4;11) is uncertain, and the benefit of allogeneic stem cell transplantation (HSCT) is unclear. We reviewed adult patients with ALL treated at our institution from 1984 to 2019 and identified 50 out of 1102 (5%) with KMT2A rearrangement, including 42 (84%) with t(4;11)/KMT2A-AFF1 and 8 (16%) with other gene partners. The median age was 45 years (range, 18-78 years); median white blood cell count was 109.0 3 109/L (range, 0.5-1573.0). The complete remission (CR) rate was 88%, and the rate of measurable residual disease negativity by flow cytometry at CR was 41% (76% overall during follow-up). At the last follow-up, 14 patients were alive. The 5-year overall survival (OS) rate was 18% (95% confidence interval [CI], 9% to 35%), with no difference between t(4;11) and other KMT2A rearrangements (P 5 .87). In a 4-month landmark analysis, the 5-year OS rate was 32% (95% CI, 14% to 70%) in patients who underwent HSCT vs 11% (95% CI, 3-39) in others (P 5 .10). Our study confirms the poor prognosis of ALL with any KMT2A rearrangement and the role of HSCT in these patients.
引用
- Richard-Carpentier G, Kantarjian HM, Tang G, et al. Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience. Blood Adv. 2021. PMID: 34525185. doi:10.1182/bloodadvances.2021004580
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。